FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andres Schrader

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Thomas Schnoeller; Mark Schrader; Friedemann Zengerling; Marcus V Cronauer; Ilija Damjanoski; Andreas Al Ghazal; Florian Jentzmik; Ludwig Rinnab; Andres J Schrader
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
T J Schnoeller; M Schrader; J Steinestel; F Zengerling; A Al Ghazal; Robert De Petriconi; R Hefty; F Jentzmik; J Mueller; Andres J Schrader
[The use of Surgisis® optimizes and simplifies partial nephrectomy for large renal tumors].
Sandra Steffens; Julie Steinestel; Gerd Wegener; Mark Schrader; Andreas Al Ghazal; Marcus V Cronauer; Florian Jentzmik; Markus A Kuczyk; Rieke Lehmann; Thomas J Schnoeller; Andres J Schrader
High CRP values predict poor survival in patients with penile cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andres Schrader (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thomas Schnoeller; Mark Schrader; Friedemann Zengerling; Marcus V Cronauer; Ilija Damjanoski; Andreas Al Ghazal; Florian Jentzmik; Ludwig Rinnab; Andres J Schrader
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
World journal of urology 2013;31(2):253-9.
2013: T J Schnoeller; M Schrader; J Steinestel; F Zengerling; A Al Ghazal; Robert De Petriconi; R Hefty; F Jentzmik; J Mueller; Andres J Schrader
[The use of Surgisis® optimizes and simplifies partial nephrectomy for large renal tumors].
Der Urologe. Ausg. A 2013;52(2):246-51.
2013: Sandra Steffens; Julie Steinestel; Gerd Wegener; Mark Schrader; Andreas Al Ghazal; Marcus V Cronauer; Florian Jentzmik; Markus A Kuczyk; Rieke Lehmann; Thomas J Schnoeller; Andres J Schrader
High CRP values predict poor survival in patients with penile cancer.
BMC cancer 2013;13():223.
2012: Sandra Steffens; Michael Stöckle; Joachim W Thüroff; Gerd Wegener; Mark Schrader; Simon Schumacher; Christoph Seidel; Stefan Siemer; Frank Becker; Arndt Hartmann; Rainer Hofmann; Martin Janssen; Kerstin Junker; Markus A Kuczyk; Frederik C Roos; Andres J Schrader
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
European journal of cancer (Oxford, England : 1990) 2012;48(15):2347-52.
2012: Andres J Schrader; Mark Schrader; Sandra Steffens; Thomas J Schnoeller; Markus A Kuczyk
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
International journal of urology : official journal of the Japanese Urological Association 2012;19(10):903-7.
2012: Katharina Sell; Martin A Thomas; Nadine Zimmer; Mark Schrader; Peter J Barth; Michael Gudo; Rainer Hofmann; Roland Moll; Ecatarina Oplesch; Andres J Schrader
Localization of FOXP3-positive cells in renal cell carcinoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(2):507-13.
2012: Sandra Steffens; Gerd Wegener; Mark Schrader; Christoph Seidel; Hendrik Eggers; Martin Janssen; Astrid Köhler; Markus A Kuczyk; Raphael Rudolph; Andres J Schrader
Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.
BMC cancer 2012;12():399.
2011: S Waalkes; G Wegener; H Eggers; R Hofmann; M Janssen; Markus A Kuczyk; F C Roos; Andres J Schrader; M Schrader; S Schumacher; J W Thüroff
[Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
Der Urologe. Ausg. A 2011;50(9):1125-9.
2011: S Waalkes; G Wegener; H Eggers; R Hofmann; F Jentzmik; Markus A Kuczyk; J Rustemeier; Andres J Schrader; M Schrader
[Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer].
Der Urologe. Ausg. A 2011;50(9):1118-24.
2011: Sandra Waalkes; Hendrik Eggers; Hanna Blasig; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Wolfgang Tränkenschuh; Arnulf Stenzl; Jürgen Serth; Andres J Schrader; Markus A Kuczyk; Axel S Merseburger
Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer.
Biomarkers in medicine 2011;5(2):219-25.
2011: Sandra Steffens; Wolfgang Tränkenschuh; Gesa Vetter; Hanna Blasig; Hendrik Eggers; Markus A Kuczyk; Andres J Schrader; Jürgen Serth
Caveolin 1 protein expression in renal cell carcinoma predicts survival.
BMC urology 2011;11():25.
2011: Sandra Steffens; Frank Wacker; Mark Schrader; Christoph Seidel; Hendrik Eggers; Viktor Grünwald; Markus A Kuczyk; Kristina I Ringe; Andres J Schrader
Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
The oncologist 2011;16(11):1565-71.
2011: Sandra Waalkes; Hendrik Rott; Thomas Herrmann; Gerd Wegener; Mario W Kramer; Axel S Merseburger; Mark Schrader; Rainer Hofmann; Markus A Kuczyk; Andres J Schrader
Does male sex influence the prognosis of patients with renal cancer?
Onkologie 2011;34(1-2):24-8.
2010: Sandra Waalkes; Axel S Merseburger; Mario W Kramer; Thomas Herrmann; Gerd Wegener; Julia Rustemeier; Rainer Hofmann; Mark Schrader; Markus A Kuczyk; Andres J Schrader
Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer.
Cancer causes & control : CCC 2010;21(11):1905-10.
2010: S Sevinc; C C Westhoff; Andres J Schrader; Peter Olbert; R Hofmann; Axel Hegele
[Pelvic lymphadenitis after total hip arthroplasty : Mimicking of lymph node metastases in a patient with prostate cancer].
Der Urologe. Ausg. A 2010;49(8):952-6.
2010: Sandra Waalkes; Axel S Merseburger; Thomas Herrmann; Mario W Kramer; Gerd Wegener; Julia Rustemeier; Rainer Hofmann; Markus A Kuczyk; Andres J Schrader
Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma.
World journal of urology 2010;28(3):283-8.
2010: C Frohme; Z Varga; Peter Olbert; Andres J Schrader; R Hofmann; Axel Hegele
[Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].
Der Urologe. Ausg. A 2010;49(5):639-44.
2010: Peter Olbert; Christian Keil; Jost Weber; Andres J Schrader; Axel Hegele; Rainer Hofmann
Efficacy and safety of the Accordion stone-trapping device: in vitro results from an artificial ureterolithotripsy model.
Urological research 2010;38(1):41-6.
2010: Sandra Waalkes; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Gesa Vetter; Jan U Becker; Arnulf Stenzl; Axel S Merseburger; Andres J Schrader; Markus A Kuczyk; Jürgen Serth
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer.
BMC cancer 2010;10():503.
2009: C Frohme; E M Walthers; Andres J Schrader; Peter Olbert; R Hofmann; Axel Hegele
[Intrathoracic hernia after laparoscopic nephrectomy: clinical manifestation and conservative management].
Der Urologe. Ausg. A 2009;48(12):1499-502.
2009: Andres J Schrader; Julia Rustemeier; Jan Christoph Rustemeier; Nina Timmesfeld; Zoltan Varga; Axel Hegele; Peter Olbert; Rainer Hofmann
Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma.
Journal of cancer research and clinical oncology 2009;135(12):1693-9.
2009: Peter Olbert; Andres J Schrader; Corinna Simon; Alexander H Dalpke; Peter Barth; Rainer Hofmann; Axel Hegele
In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Anticancer research 2009;29(6):2067-76.
2009: Andres J Schrader; S Rauer-Bruening; Peter Olbert; Axel Hegele; J Rustemeier; N Timmesfeld; Z Varga; Rainer Hofmann
Incidence and long-term prognosis of papillary renal cell carcinoma.
Journal of cancer research and clinical oncology 2009;135(6):799-805.
2009: Peter Olbert; C Weil; Axel Hegele; Rainer Hofmann; Andres J Schrader
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Aktuelle Urologie 2009;40(3):164-8.
2009: Peter Olbert; L Baumann; Axel Hegele; Andres J Schrader; R Hofmann
[Fast-track concepts in the perioperative management of patients undergoing radical cystectomy and urinary diversion: review of the literature and research results].
Der Urologe. Ausg. A 2009;48(2):137-42.
2009: Sandra Machold; Peter Olbert; Axel Hegele; Georg Kleinhans; Rainer Hofmann; Andres J Schrader
Comparison of a 20-min pad test with the 1-hour pad test of the international continence society to evaluate post-prostatectomy incontinence.
Urologia internationalis 2009;83(1):27-32.
2009: Andreas Jeron; Susanne Pfoertner; Dunja Bruder; Robert Geffers; Peter Hammerer; Rainer Hofmann; Jan Buer; Andres J Schrader
Frequency and gene expression profile of regulatory T cells in renal cell carcinoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2009;30(3):160-70.
2008: Peter Olbert; Andres J Schrader; R Hofmann; Axel Hegele
[Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression].
Der Urologe. Ausg. A 2008;47(9):1133-4, 1136.
2008: Andres J Schrader; S Sevinc; Peter Olbert; Axel Hegele; Z Varga; Rainer Hofmann
[Gender-specific characteristics and survival of renal cell carcinoma].
Der Urologe. Ausg. A 2008;47(9):1182, 1184-6.
2008: Axel Hegele; B Kosche; Andres J Schrader; S Sevinc; Peter Olbert; R Hofmann; J Kropf
[Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker].
Der Urologe. Ausg. A 2008;47(9):1137-40.
2008: Andres J Schrader; Peter Olbert; Axel Hegele; Zoltan Varga; Rainer Hofmann
Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
BJU international 2008;101(11):1343-5.
2008: Diana J Leeming; Axel Hegele; Inger Byrjalsen; Rainer Hofmann; Per Qvist; Morten A Karsdal; Andres J Schrader; Reinhold Wagner; Peter Olbert
Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(5):1269-76.
2008: Andres J Schrader; Rainer Hofmann
Metastatic renal cell carcinoma: recent advances and current therapeutic options.
Anti-cancer drugs 2008;19(3):235-45.
2007: Peter Olbert; Axel Hegele; Andres J Schrader; André Scherag; Rainer Hofmann
Pre- and perioperative predictors of short-term clinical outcomes in patients undergoing percutaneous nephrolitholapaxy.
Urological research 2007;35(5):225-30.
2007: Andres J Schrader; M Seger; L Konrad; Peter Olbert; Axel Hegele; Rainer Hofmann; A Heidenreich
Clinical impact of MDR1-expression in testicular germ cell cancer.
Experimental oncology 2007;29(3):212-6.
2007: Andres J Schrader; Axel Hegele; Peter Olbert; Jan Buer; Andreas Jeron; R Hofmann
[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Der Urologe. Ausg. A 2007;46(9):1291.
2007: Peter Olbert; Andres J Schrader; Axel Hegele; Rainer Hofmann
[Focus on tumor immunology of transitional cell carcinoma].
Der Urologe. Ausg. A 2007;46(9):1135-7.
2007: Axel Hegele; Hans Günther Wahl; Zoltan Varga; Selim Sevinc; Liseta Koliva; Andres J Schrader; Rainer Hofmann; Peter Olbert
Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
BJU international 2007;99(2):330-4.
2006: Andres J Schrader; A Heidenreich; Axel Hegele; Peter Olbert; Z Varga; R Hofmann
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Aktuelle Urologie 2006;37(6):429-35; quiz 423-4.
2006: Peter Olbert; Axel Hegele; Petra Kraeuter; Axel Heidenreich; Rainer Hofmann; Andres J Schrader
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
Anti-cancer drugs 2006;17(8):993-6.
2006: Carsten-Henning Ohlmann; Enver Ozgür; Andres J Schrader; Lutz Konrad; Rainer Hofmann; Udo Engelmann; Axel Heidenreich
Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA-9: results of a prospective trial.
Urologic oncology 2006;24(4):287-93.
2006: Andres J Schrader; Zoltan Varga; Susanne Pfoertner; Ulrike Goelden; Jan Buer; Rainer Hofmann
Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
BJU international 2006;97(3):461-5.
2006: Andres J Schrader; Z Varga; Axel Hegele; Susanne Pfoertner; Peter Olbert; Rainer Hofmann
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.
Journal of cancer research and clinical oncology 2006;132(3):137-49.
2006: Andres J Schrader; Carsten-Henning Ohlmann; Sandra Rossmanith; Rainer Hofmann; Axel Heidenreich
Impact of evidence-based interdisciplinary guidelines on testis cancer management.
Cancer 2006;106(2):313-9.
2006: Susanne Pfoertner; Andreas Jeron; Michael Probst-Kepper; Carlos A Guzman; Wiebke Hansen; Astrid M Westendorf; Tanja Toepfer; Andres J Schrader; Anke Franzke; Jan Buer; Robert Geffers
Signatures of human regulatory T cells: an encounter with old friends and new players.
Genome biology 2006;7(7):R54.
2006: Zoltan Varga; Axel Hegele; Peter Olbert; Rainer Hofmann; Andres J Schrader
Laparoscopic peritoneal drainage of symptomatic lymphoceles after pelvic lymph node dissection using methylene blue instillation.
Urologia internationalis 2006;76(4):335-8.
2005: Susanne Pfoertner; Ulrike Goelden; Wiebke Hansen; Tanja Toepfer; Robert Geffers; Sya N Ukena; Rolf von Knobloch; Rainer Hofmann; Jan Buer; Andres J Schrader
Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(6):313-23.
2005: Ulrike Goelden; Sya N Ukena; Susanne Pfoertner; Rainer Hofmann; Jan Buer; Andres J Schrader
RAR-beta(1) overexpression in chromophobe renal cell carcinoma: a novel target for therapeutic intervention?
Experimental oncology 2005;27(3):220-4.
2005: Andres J Schrader; Axel Heidenreich; Axel Hegele; Peter Olbert; Carsten-Henning Ohlmann; Zoltan Varga; Rolf von Knobloch; Rainer Hofmann
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
Anti-cancer drugs 2005;16(5):581-5.
2005: Ulrike Goelden; Susanne Pfoertner; Wiebke Hansen; Tanja Toepfer; Rolf von Knobloch; Rainer Hofmann; Jan Buer; Andres J Schrader
Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.
Urologia internationalis 2005;75(3):269-76.
2004: Andres J Schrader; Rolf von Knobloch; Axel Heidenreich; Jan Buer; Rainer Hofmann
Application of retinoids in the treatment of renal cell carcinoma--a futile effort?
Anti-cancer drugs 2004;15(9):819-24.
2004: Axel Heidenreich; Frank Sommer; Carsten-Henning Ohlmann; Andres J Schrader; Peter Olbert; Joachim Goecke; Udo Engelmann
Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Cancer 2004;101(5):948-56.
2004: Rolf von Knobloch; Heidrun Brandt; Andres J Schrader; Axel Heidenreich; Rainer Hofmann
Molecular serological detection of DNA alterations in transitional cell carcinoma is highly sensitive and stage independent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):988-93.
2003: Axel Heidenreich; Andres J Schrader; Zoltan Varga
Basic science and research in renal cell carcinoma: from workbench to bedside.
Current opinion in urology 2003;13(6):457-62.
2003: Andres J Schrader; Georgia Anderer; Rolf von Knobloch; Axel Heidenreich; Rainer Hofmann
Giant hydronephrosis mimicking progressive malignancy.
BMC urology 2003;3():4.
2003: Andres J Schrader; Jörg Lauber; Oskar Lechner; Axel Heidenreich; Rainer Hofmann; Jan Buer
Application of real-time reverse transcriptase-polymerase chain reaction in urological oncology.
The Journal of urology 2003;169(5):1858-64.
2002: Andres J Schrader; Oskar Lechner; M Templin; Kurt E J Dittmar; S Machtens; Michael Mengel; Michael Probst-Kepper; Anke Franzke; T Wollensak; Patricia Gatzlaff; Jens Atzpodien; Jan Buer; Jörg Lauber
CXCR4/CXCL12 expression and signalling in kidney cancer.
British journal of cancer 2002;86(8):1250-6.
2001: Anke Franzke; Jan Buer; Michael Probst-Kepper; C Lindig; M Framzle; Andres J Schrader; Arnold Ganser; Jens Atzpodien
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Cancer biotherapy & radiopharmaceuticals 2001;16(5):401-9.
2000: Andres J Schrader; J Atzpodien
High-dose chemotherapy with autologous stem-cell transplantation in patients with pretreated advanced malignant melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1361-2.
2000: Andres J Schrader; Michael Probst-Kepper; Jens Grosse; U Kunter; Anke Franzke; Saadettin Sel; E Atzpodien; Jan Buer
Tumour microdissemination and survival in metastatic melanoma.
Anticancer research 2000;20(5B):3619-24.
2000: K Oevermann; Jan Buer; Reinhard Hoffmann; Anke Franzke; Andres J Schrader; T Patzelt; Holger Kirchner; Jens Atzpodien
Capecitabine in the treatment of metastatic renal cell carcinoma.
British journal of cancer 2000;83(5):583-7.
2000: Andres J Schrader; Michael Probst-Kepper; Jens Grosse; U Kunter; F Schenk; Anke Franzke; Jens Atzpodien; Jan Buer
Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.
Melanoma research 2000;10(4):355-62.
2000: Andres J Schrader
Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
Anti-cancer drugs 2000;11(3):143-8.
1999: Carola Berking; EM Schlüpen; Andres J Schrader; J Atzpodien; Matthias Volkenandt
Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100.
Archives of dermatological research 1999;291(9):479-84.
1997: Michael Probst-Kepper; Andres J Schrader; Jan Buer; Jens Grosse; M Volkenandt; Hans-Jochen Illiger; Bernd Metzner; Janos Kadar; Stefan Duensing; Bernd Hertenstein; Arnold Ganser; Jens Atzpodien
Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma.
British journal of haematology 1997;98(2):488-90.